Jason Bednar
Stock Analyst at Piper Sandler
(2.14)
# 1,486
Out of 4,667 analysts
147
Total ratings
44.78%
Success rate
n/a
Average return
Main Sectors:
Stocks Rated by Jason Bednar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KRMD KORU Medical Systems | Maintains: Overweight | $3 → $3.5 | $3.65 | -4.11% | 5 | Nov 14, 2024 | |
| SOLV Solventum | Maintains: Neutral | $71 → $75 | $68.40 | +9.66% | 2 | Nov 8, 2024 | |
| MDXH MDxHealth | Maintains: Overweight | $8 → $6 | $1.62 | +270.37% | 5 | Nov 7, 2024 | |
| MASI Masimo | Maintains: Overweight | $165 → $180 | $164.95 | +9.12% | 12 | Nov 6, 2024 | |
| NVST Envista Holdings | Maintains: Neutral | $16 → $17 | $20.37 | -16.54% | 10 | Oct 31, 2024 | |
| ALGN Align Technology | Maintains: Overweight | $285 → $275 | $223.87 | +22.84% | 27 | Oct 24, 2024 | |
| STE STERIS | Upgrades: Overweight | $230 → $260 | $212.25 | +22.50% | 8 | Oct 24, 2024 | |
| MMSI Merit Medical Systems | Reiterates: Overweight | $100 → $110 | $104.08 | +5.69% | 7 | Sep 9, 2024 | |
| COO The Cooper Companies | Reiterates: Overweight | $115 → $120 | $99.08 | +21.11% | 11 | Aug 29, 2024 | |
| DRTS Alpha Tau Medical | Reiterates: Overweight | $7 | $2.30 | +205.01% | 5 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $3.5 → $1 | $0.49 | +103.42% | 3 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $12 | $6.20 | +93.55% | 10 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $86 | $73.73 | +16.64% | 6 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $13 | $13.21 | -1.59% | 1 | May 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $35 → $32 | $18.52 | +72.79% | 7 | May 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $25 → $28 | $16.86 | +66.07% | 8 | Apr 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $34 → $28 | $20.06 | +39.58% | 7 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $310 → $372 | $541.82 | -31.34% | 4 | Jan 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $9 | $2.45 | +267.35% | 2 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $305 → $280 | $221.29 | +26.53% | 6 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $95 | $84.90 | +11.90% | 1 | Apr 19, 2023 |
KORU Medical Systems
Nov 14, 2024
Maintains: Overweight
Price Target: $3 → $3.5
Current: $3.65
Upside: -4.11%
Solventum
Nov 8, 2024
Maintains: Neutral
Price Target: $71 → $75
Current: $68.40
Upside: +9.66%
MDxHealth
Nov 7, 2024
Maintains: Overweight
Price Target: $8 → $6
Current: $1.62
Upside: +270.37%
Masimo
Nov 6, 2024
Maintains: Overweight
Price Target: $165 → $180
Current: $164.95
Upside: +9.12%
Envista Holdings
Oct 31, 2024
Maintains: Neutral
Price Target: $16 → $17
Current: $20.37
Upside: -16.54%
Align Technology
Oct 24, 2024
Maintains: Overweight
Price Target: $285 → $275
Current: $223.87
Upside: +22.84%
STERIS
Oct 24, 2024
Upgrades: Overweight
Price Target: $230 → $260
Current: $212.25
Upside: +22.50%
Merit Medical Systems
Sep 9, 2024
Reiterates: Overweight
Price Target: $100 → $110
Current: $104.08
Upside: +5.69%
The Cooper Companies
Aug 29, 2024
Reiterates: Overweight
Price Target: $115 → $120
Current: $99.08
Upside: +21.11%
Alpha Tau Medical
Aug 15, 2024
Reiterates: Overweight
Price Target: $7
Current: $2.30
Upside: +205.01%
Aug 7, 2024
Maintains: Overweight
Price Target: $3.5 → $1
Current: $0.49
Upside: +103.42%
Aug 1, 2024
Maintains: Overweight
Price Target: $14 → $12
Current: $6.20
Upside: +93.55%
Jun 21, 2024
Reiterates: Overweight
Price Target: $86
Current: $73.73
Upside: +16.64%
May 21, 2024
Initiates: Neutral
Price Target: $13
Current: $13.21
Upside: -1.59%
May 3, 2024
Reiterates: Neutral
Price Target: $35 → $32
Current: $18.52
Upside: +72.79%
Apr 10, 2024
Reiterates: Overweight
Price Target: $25 → $28
Current: $16.86
Upside: +66.07%
Feb 29, 2024
Downgrades: Neutral
Price Target: $34 → $28
Current: $20.06
Upside: +39.58%
Jan 3, 2024
Maintains: Outperform
Price Target: $310 → $372
Current: $541.82
Upside: -31.34%
Nov 10, 2023
Maintains: Overweight
Price Target: $14 → $9
Current: $2.45
Upside: +267.35%
Nov 10, 2023
Maintains: Overweight
Price Target: $305 → $280
Current: $221.29
Upside: +26.53%
Apr 19, 2023
Initiates: Overweight
Price Target: $95
Current: $84.90
Upside: +11.90%